Last update :
06/12/2024
References   References 4819  
Type : Journal
Web link : https://doi.org/10.1016/j.ijpharm.2023.123643

Research teams : Padua - Department of Pharmaceutical and Pharmacological Sciences, University of Padua
Authors : Carpanese D, Rossi V, Di Paolo V, Quintieri L, Penna Zuccolotto G, Sebellin J, Saran C, Pipitone F, Miolo G, de Diana E et al.
Title : Prolonging the stability of cetuximab (Erbitux®) and panitumumab (Vectibix®): An orthogonal assessment of physicochemical, biological and microbiological properties of original opened glass vials and diluted saline preparations.
Reference : Int J Pharm ; 649: 123643. 2024

Level of Evidence : 
Level of evidence A+
Physical stability : 
Visual examination Turbidimetry Protein: Size Exclusion Chromatography 
Chemical stability : 
ultraviolet spectrometry
Protein: ultraviolet spectrometry and second derivative
Capillary electrophoresis
Other methods : 
PH measurement Protein: biological activity 
Comments : 
Proteins: biological activity by cell culture

List of drugs
injectionCetuximab Anticancer drug
Stability in solutions partially used vials None 5 mg/ml 2-8°C Protect from light
180 Day
Stability in solutions Polyolefine Sodium chloride 0,9% 1,5 & 4 mg/ml 2-8°C Protect from light
30 Day
Stability in solutions Polyolefine Sodium chloride 0,9% 1,5 & 4 mg/ml 25°C Protect from light
15 Hour
injectionPanitumumab Anticancer drug
Stability in solutions partially used vials None 20 mg/ml 2-8°C Protect from light
180 Day
Stability in solutions Polyolefine Sodium chloride 0,9% 3 & 6 mg/ml 2-8°C Protect from light
30 Day
Stability in solutions Polyolefine Sodium chloride 0,9% 3 & 6 mg/ml 25°C Protect from light
15 Hour

  Mentions Légales